3 research outputs found
Produção e decomposição de folhedo em um trecho de Mata Atlântica de encosta no município do Guarujá, SP
A produção de folhedo e a taxa de decomposição de folhedo (k) foram estimadas, no período de 2.8.85 a 10.8.86, numa área de 1 ha de mata atlântica de encosta (60º de inclinação e altitude de 140m), no município do Guarujá (Lat. S 24º16'; Long. W 46º19'), Estado de São Paulo. A queda pluviométrica anual média é de 2050 mm e não há estação seca definida. O solo é argilo-arenoso e ácido, com pH variando entre 3 e 4. A produção anual de folhedo foi de 7925 kg/ha. A fração folhas contribuiu com 5040 kg/ha seguida pelas frações ramos (1950 kg/ha), flores (491 kg/ha), frutos (222 kg/ha) e material de origem animal (222 kg/ha). A produção de folhedo e das frações componentes foi contínua durante todo o ano. Os valores mensais de produção não revelaram nenhum padrão sazonal. A taxa de decomposição (k) foi estimada para condições de equilíbrio dinâmico (0,72) e também utilizando a porcentagem de peso remanescente da fração foliar (0,83). O tempo médio para a decomposição de 50% do folhedo foi de 350 dias.<br>Litter production and decomposition rate were studied in 1 ha of hillside atlantic forest (60? inclination and 140m high) located at Guarujá (24º 16' S; 46º 19' W) of São Paulo State from 2.8.85 to 10.8.86. This area have not a defined dry season and the annual average rainfall is 2050 mm. The soil is classified as acidic and clay-sand with pH 3.0-4.0. The annual litter production was estimated at 7925 kg/ha: comprising leaves fraction contributing with 5040 kg/ha, followed by branches (1950 kg/ha), flowers (491 kg/ha), fruits (222 kg/ha) and animal products (222 kg/ha). All fractions were produced during all over the year, without any detectable seazonal pattern. The decomposition constant (k) was estimated for steady-state conditions (0,72) and also utilizing the percentage of remaining weight of foliar fraction (0,83). The time necessary for 50% of the litter decomposition was 350 days
Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation
Rationale Asthma phenotyping requires novel biomarker discovery. Objectives To identify plasma biomarkers associated with asthma phenotypes by application of a new proteomic panel to samples from two well-characterised cohorts of severe (SA) and mild-to-moderate (MMA) asthmatics, COPD subjects and healthy controls (HCs). Methods An antibody-based array targeting 177 proteins predominantly involved in pathways relevant to inflammation, lipid metabolism, signal transduction and extracellular matrix was applied to plasma from 525 asthmatics and HCs in the U-BIOPRED cohort, and 142 subjects with asthma and COPD from the validation cohort BIOAIR. Effects of oral corticosteroids (OCS) were determined by a 2-week, placebo-controlled OCS trial in BIOAIR, and confirmed by relation to objective OCS measures in U-BIOPRED. Results In U-BIOPRED, 110 proteins were significantly different, mostly elevated, in SA compared to MMA and HCs. 10 proteins were elevated in SA versus MMA in both U-BIOPRED and BIOAIR (alpha-1-antichymotrypsin, apolipoprotein-E, complement component 9, complement factor I, macrophage inflammatory protein-3, interleukin-6, sphingomyelin phosphodiesterase 3, TNF receptor superfamily member 11a, transforming growth factor-β and glutathione S-transferase). OCS treatment decreased most proteins, yet differences between SA and MMA remained following correction for OCS use. Consensus clustering of U-BIOPRED protein data yielded six clusters associated with asthma control, quality of life, blood neutrophils, high-sensitivity C-reactive protein and body mass index, but not Type-2 inflammatory biomarkers. The mast cell specific enzyme carboxypeptidase A3 was one major contributor to cluster differentiation. Conclusions The plasma proteomic panel revealed previously unexplored yet potentially useful Type-2independent biomarkers and validated several proteins with established involvement in the pathophysiology of SA. © 2022 European Respiratory Society. All rights reserved